Comparable Antileukemia/Lymphoma Effects in Nonremission Patients Undergoing Allogeneic Hematopoietic Cell Transplantation with a Conventional Cytoreductive or Reduced-Intensity Regimen

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 8, 2007, Pages 932-941

  Maruyama, Dai ^a   Fukuda, Takahiro ^a   Kato, Ruri ^a   Yamasaki, Satoshi ^a   Usui, Eiji ^a   Morita Hoshi, Yuriko ^a   Kim, Sung Won ^a   Mori, Shin ichiro ^a   Heike, Yuji ^a   Makimoto, Atsushi ^a   Tajima, Kinuko ^a   Tanosaki, Ryuji ^a   Tobinai, Kensei ^a   Takaue, Yoichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Leukemia; Lymphoma; Transplantation

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; BUSULFAN; CIPROFLOXACIN; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; COMORBIDITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HIGH RISK PATIENT; HLA MATCHING; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYCOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PROBABILITY; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JAPAN; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447332877     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.004     Document Type: Article

References (38)

1. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
2. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21 (2003) 1480-1484
3. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
4. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
5. Alyea E.P., Haesook T., Soiffer R.J., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
6. Valcá rcel D., Martino R., Sierra J., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 74 (2005) 144-151
7. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
8. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36 (2005) 667-674
9. Mirlcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
10. Nagler A., Slavin S., Varadi G., et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25 (2000) 1021-1028
11. Michallet M., Bilger K., Garban F., et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19 (2001) 3340-3349
12. Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24 (2006) 4150-4157
13. Maris M.B., Niederwiwser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030
14. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
15. Saito T., Kanda Y., Kami M., et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. Clin Cancer Res 8 (2002) 1014-1020
16. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
17. Kanda Y., Mineishi S., Saito T., et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28 (2001) 689-692
18. Kanda Y., Mineishi S., Saito T., et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 73 (2002) 568-572
19. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99 (2002) 1978-1985
20. Sorror M.L., Maris M.B., Storner B., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912-2919
21. Kato R., Fukuda T., Usui E., et al. Hematopoietic cell transplantation-specific comorbidity index to predict non-relapse mortality and survival after allografting. Blood 106 (2005) 766a
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
23. Przepiorka D., Weisdorf D., Martin P., et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
24. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28 (1991) 250-259
25. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 1244-1253
26. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
27. de Lima M., Anagnostopoulos A., Munsell, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
28. Martino R., Iacobelli S., de Witte T., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006) 836-846
29. Kim D.H., Sohn S.K., Baek J.H., et al. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 113 (2005) 220-227
30. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 108-114
31. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes of idiopathic pneumonia syndrome after non-myeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102 (2003) 2777-2785
32. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104 (2004) 961-968
33. Canals C., Martino R., Sureda A., et al. Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. Exp Hematol 31 (2003) 1039-1043
34. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104 (2004) 1550-1558
35. Sasazuki T., Juji T., Morishima Y., et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 339 (1998) 1177-1185
36. Junghanss C., Storb R., Maris M.B., et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 123 (2003) 662-670
37. Kanda Y., Chiba S., Hirai H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 (2003) 1541-1547
38. Arnold R., De Witte T., van Biezen A., et al., European Blood and Marrow Transplantation Group. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. Bone Marrow Transplant 21 (1998) 1213-1216